Vivos Therapeutics Files Initial Beneficial Ownership Statement

Summary

Vivos Therapeutics Inc. submitted a preliminary statement of beneficial ownership, designating Michael C. Skaff as the beneficial owner. This information was released by Vivos Therapeutics Inc. through EDGAR on June 20, 2025, and generated by PubT for reference purposes.Reuters

Impact Analysis

The submission of a statement of beneficial ownership by Vivos Therapeutics Inc. is a company-level event. This type of filing is typically of interest to investors as it can indicate changes in control or significant shareholder interests. However, without additional context on Michael C. Skaff’s role or intentions, the direct impact on Vivos’ stock price might be limited in the short term. Historically, such filings can lead to increased scrutiny from investors and analysts, potentially affecting the company’s perceived governance and strategic direction.Reuters Investors might look for further disclosures or news releases that provide insight into how this change may influence company strategy or operations.